Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Cetuximab for the treatment of colorectal cancer
Author: Jonker, D.
O'Callaghan, C.
Karapetis, C.
Zalcberg, J.
Tu, D.
Au, H.
Berry, S.
Krahn, M.
Price, T.
Simes, R.
Tebbutt, N.
van Hazel, G.
Wierzbicki, R.
Langer, C.
Moore, M.
Citation: New England Journal of Medicine, 2007; 357(20):2040-2048
Publisher: Massachusetts Medical Soc
Issue Date: 2007
ISSN: 0028-4793
Statement of
Derek J. Jonker, Chris J. O'Callaghan, Christos S. Karapetis, John R. Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott R. Berry, Marianne Krahn, Timothy Price, R. John Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer and Malcolm J. Moore
Abstract: <h4>Background</h4>Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.<h4>Methods</h4>From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival.<h4>Results</h4>In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001).<h4>Conclusions</h4>Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. ( number, NCT00079066 [].).
Keywords: Humans
Colorectal Neoplasms
Antineoplastic Agents
Antibodies, Monoclonal
Infusions, Intravenous
Survival Analysis
Aged, 80 and over
Middle Aged
Antibodies, Monoclonal, Humanized
ErbB Receptors
Rights: The New England Journal of Medicine is owned, published, and copyrighted © 2007 Massachusetts Medical Society. All rights reserved.
DOI: 10.1056/NEJMoa071834
Published version:
Appears in Collections:Aurora harvest 6
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.